Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 28

1.
3.

WITHDRAWN: Multi-agent chemotherapy for early breast cancer.

Clarke MJ.

Cochrane Database Syst Rev. 2008 Oct 8;(4):CD000487. doi: 10.1002/14651858.CD000487.pub2. Review.

PMID:
18843612
4.

Multi-agent chemotherapy for early breast cancer.

Early Breast Cancer Trialists' Collaborative Group.

Cochrane Database Syst Rev. 2002;(1):CD000487. Review. Update in: Cochrane Database Syst Rev. 2008;(4):CD000487.

PMID:
11869577
5.

WITHDRAWN: Tamoxifen for early breast cancer.

Clarke MJ.

Cochrane Database Syst Rev. 2008 Oct 8;(4):CD000486. doi: 10.1002/14651858.CD000486.pub2. Review.

PMID:
18843611
6.

Tamoxifen for early breast cancer.

Early Breast Cancer Trialists' Collaborative Group.

Cochrane Database Syst Rev. 2001;(1):CD000486. Review. Update in: Cochrane Database Syst Rev. 2008;(4):CD000486.

PMID:
11279694
7.

A systematic overview of chemotherapy effects in breast cancer.

Bergh J, J├Ânsson PE, Glimelius B, Nygren P; SBU-group. Swedish Council of Technology Assessment in Health Care.

Acta Oncol. 2001;40(2-3):253-81. Review.

PMID:
11441936
8.

Polychemotherapy for early breast cancer: an overview of the randomised clinical trials with quality-adjusted survival analysis.

Cole BF, Gelber RD, Gelber S, Coates AS, Goldhirsch A.

Lancet. 2001 Jul 28;358(9278):277-86. Review.

PMID:
11498214
9.

LHRH agonists for adjuvant therapy of early breast cancer in premenopausal women.

Sharma R, Hamilton A, Beith J.

Cochrane Database Syst Rev. 2008 Oct 8;(4):CD004562. doi: 10.1002/14651858.CD004562.pub3. Review. Update in: Cochrane Database Syst Rev. 2009;(4):CD004562.

PMID:
18843661
10.

LHRH agonists for adjuvant therapy of early breast cancer in premenopausal women.

Goel S, Sharma R, Hamilton A, Beith J.

Cochrane Database Syst Rev. 2009 Oct 7;(4):CD004562. doi: 10.1002/14651858.CD004562.pub4. Review.

PMID:
19821328
11.

Adjuvant chemotherapy in oestrogen-receptor-poor breast cancer: patient-level meta-analysis of randomised trials.

Early Breast Cancer Trialists' Collaborative Group (EBCTCG), Clarke M, Coates AS, Darby SC, Davies C, Gelber RD, Godwin J, Goldhirsch A, Gray R, Peto R, Pritchard KI, Wood WC.

Lancet. 2008 Jan 5;371(9606):29-40. doi: 10.1016/S0140-6736(08)60069-0. Review.

PMID:
18177773
12.

Current and future status of adjuvant therapy for breast cancer.

Coleman RE.

Cancer. 2003 Feb 1;97(3 Suppl):880-6. Review.

14.

Hormonal therapies for early breast cancer: systematic review and economic evaluation.

Hind D, Ward S, De Nigris E, Simpson E, Carroll C, Wyld L.

Health Technol Assess. 2007 Jul;11(26):iii-iv, ix-xi, 1-134. Review.

15.
17.

Efficacy of tamoxifen as treatment of breast cancer.

Powles TJ.

Semin Oncol. 1997 Feb;24(1 Suppl 1):S1-48-S1-54. Review.

PMID:
9045315
18.

Overview of resistance to systemic therapy in patients with breast cancer.

Gonzalez-Angulo AM, Morales-Vasquez F, Hortobagyi GN.

Adv Exp Med Biol. 2007;608:1-22. Review.

PMID:
17993229
19.

Adjuvant chemotherapy in the node-negative breast cancer patient.

Styblo TM, Wood WC.

Surg Clin North Am. 1996 Apr;76(2):327-41. Review.

PMID:
8610267
20.

Systemic therapy for treating locoregional recurrence in women with breast cancer.

Rauschecker H, Clarke M, Gatzemeier W, Recht A.

Cochrane Database Syst Rev. 2001;(4):CD002195. Review.

PMID:
11687148

Supplemental Content

Support Center